The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...

The impact of preoperative glucagon-like peptide-1 receptor agonists (GLP1RA) utilization on bariatric surgery outcomes, ...

The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most ..

MBX Biosciences, Inc.’s MBX share price has dipped by 14.00%, which has investors questioning if this is right time to buy.